Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00156897
Status:
COMPLETED
Last Update Posted:
2006-08-29
First Post:
2005-09-08
Brief Title:
Efficacy and Safety of ATL-962 in Obese Diabetics
Sponsor:
Alizyme
Organization:
Alizyme
Study Overview
Official Title:
Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin in Comparison With Orlistat
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
Detailed Description:
Obesity is a significant and increasing clinical problem There is a need for effective therapeutic agents to help people reduce weight ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a persons diet leading to weight reduction
In this study patients with Type II diabetes who are clinically obese will receive ATL-962 at one of three dose levels or placebo or orlistat another lipase inhibitor The study will investigate the amount of weight lost after 12 weeks treatment and will compare the safety and tolerability profile of ATL-962 and orlistat
In this study patients with Type II diabetes who are clinically obese will receive ATL-962 at one of three dose levels or placebo or orlistat another lipase inhibitor The study will investigate the amount of weight lost after 12 weeks treatment and will compare the safety and tolerability profile of ATL-962 and orlistat
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None